ADVL1416, A Phase 1 study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid tumors, including CNS Tumors
Sponsor: |
Eli Lilly and Company |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAQ5801 |
U.S. Govt. ID: |
NCT02564198 |
Contact: |
Alice Lee, MD: 212-305-5808 / al2041@cumc.columbia.edu |
The goals of this study are to find the highest safe dose of ramucirumab that can be given without causing severe side effects, to learn what kind of side effects ramucirumab can cause, to learn more about the effects of ramucirumab on cells and proteins in the blood and to determine whether ramucirumab is a beneficial treatment for patients with solid tumors.
This study is closed
Investigator
Alice Lee, MD
Has your child been diagnosed with solid tumors? |
Yes |
No |